Holman Ballesteros-Gómez

Oncólogo Radioterápico MSc

[Muhammad Ali @dr_alimuhammad]

Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.

https://t.co/07jeA1lQMb

[lina loaiza @linaloa86282374]

Un honor contar con tu participación en este encuentro sobre cáncer e inteligencia artificial. Los avances tecnológicos continúan reforzando el papel esencial de la radioterapia en el manejo oncológico. @fcounago

[María Caicedo MD @MaraCaicedo19]

I am so happy to share with you this historic perspective of radiation therapy for locally advanced cervical cancer. I will be forever grateful for the opportunity to contribute in this special issue of the @IJGConline. @andresafa96 @AndrewFarach

[Ricardo Soares @soares_uro]

Not every Gleason 3+4 should be on active surveillance. Consider:
- amount of pattern 4 (number of cores and % core)
- PSA density
- cribriform or intraductal
- PI-RADS (also capsular involvement)
- Decipher
@MayoUrology #MayoUroHawaii26

[Carolina Wiesner @WiesnerCarolina]

@AACR en @INCancerologia la importancia de promover las ciencias de la implementacion en Colombia

[Carolina Wiesner @WiesnerCarolina]

@INCancerologia @MinSaludCol https://t.co/2GeQfIiWmg

[Shuhua (Steve) Zheng @zheng_shuhua]

RT all the way

[Jorge Rodríguez @jlrodriguezsar]

El techo de la iglesia de Guatavita, una joya del arquitecto Ponce de León. 🌟
@colombia_hist

[Jorge Rodríguez @jlrodriguezsar]

Un rayo de sol posado en el árbol. Así se ve la belleza en Santander, Colombia 🇨🇴 💛🌳

#AvesDeColombia #Birdwatching #Santander @colombia_hist #villanueva #barichara

[David Palma, MD, PhD @drdavidpalma]

Here's a patient recently randomized on our ARREST2 phase 2/3 RCT.

Sixteen pulmonary mets, 35 Gy in 5 fractions.

Constraints: V13.5 Gy <37%, 1500 cc of lung <12.5 Gy

[ASTRO @ASTRO_org]

New in #practicalRO: The New Paradigm of Simulation-Free Radiotherapy: Practical Recommendations for Successful Clinical Implementation. #radonc https://t.co/RvZbyo1laO

[NEJM @NEJM]

In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: https://t.co/RVh16xfI1z

Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer https://t.co/0uZLKwivM5

[Holman Ballesteros-Gómez @ballesterosh_87]

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | New England Journal of Medicine https://t.co/kWXSCOG7kK

[Milos Grujic @grujicmilos10]

📘 New Meta-analysis:
Is salvage radiotherapy (SRT) safe after failed HIFU or cryotherapy for prostate cancer?
✅ Low acute & late grade ≥3 GI/GU toxicity
✅ ~80% biochemical relapse-free survival
❗ SRT appears safer post-cryotherapy vs HIFU

@BarbaraJereczek @GiuliaMarvaso84 @Mat_Guc @ZilliThomas @StAr_MCM74 @alongi_filippo @CZamboglou

🧠 #RadiationOncology #ProstateCancer #SRT #HIFU #Cryotherapy #OncoHighlights

[David Sher @DavidSherMD]

Incredible study on HNSCC ENI now published in @JCO_ASCO

Randomized-controlled trial on ENI dose de-escalation

Nominal dose 50 Gy vs. 43 Gy in 34 fractions

EQD2 44 Gy vs 34 Gy

6 fractions per week, **NO CHEMOTHERAPY**

https://t.co/5yMiGPqfKS

[Dr. Nina Niu Sanford @NiuSanford]

Question re: OAR constraints for rectal RT.

What constraints do you use for bowel? I think tough b/c toxicities can be unpredictable, & depending on tumor location may need to exceed.

I put in chart from PRO pub in video, & our Timmerman constraints are below:

[Gustavo @gusviani]

📢 ESMO 2025: The Expanding Role of Radiotherapy in HCC🚨 @OncoAlert

🔬 The 2025 ESMO Guidelines now recognize ☢️ as a key treatment for hepatocellular carcinoma (HCC) across multiple stages

From curative SBRT to palliative RT for symptom control, here’s how ☢️is transforming HCC management! 🧵👇

[Krishan Jethwa @KrishanJethwa]

🔥NRG GI-007🔥

LA-Esophagus Carcinoma
🔍 dCRT (50.4 Gy/28 fx carbo/taxol) + endoscopically injected oncolytic virus OBP-301

✅💯 cCR rate❗️
✅Comparatively favorable AE profile

👏🏽👏🏽 Brilliant work and looking forward to future study!!

#GI25 @ASCO @NRGonc